Exactech (NASDAQ:EXAC) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other brokerages also recently weighed in on EXAC. Robert W. Baird set a $34.00 price objective on Exactech and gave the company a “buy” rating in a research report on Sunday, October 15th. Zacks Investment Research downgraded Exactech from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. Gabelli downgraded Exactech from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Sidoti downgraded Exactech from a “buy” rating to a “neutral” rating in a research report on Monday, October 23rd. Finally, ValuEngine downgraded Exactech from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the company. The company currently has an average rating of “Hold” and an average target price of $49.00.

Shares of Exactech (NASDAQ:EXAC) traded down $0.15 on Friday, reaching $50.00. The company’s stock had a trading volume of 183,861 shares, compared to its average volume of 99,488. The stock has a market capitalization of $723.36, a price-to-earnings ratio of 2,500.00, a P/E/G ratio of 3.70 and a beta of 1.02. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.09 and a current ratio of 4.08. Exactech has a 1-year low of $23.30 and a 1-year high of $50.95.

Exactech (NASDAQ:EXAC) last issued its earnings results on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.23 by ($0.03). The firm had revenue of $61.40 million during the quarter, compared to analysts’ expectations of $61.78 million. Exactech had a return on equity of 7.22% and a net margin of 0.18%. equities research analysts anticipate that Exactech will post 1.29 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the business. TIAA CREF Investment Management LLC raised its holdings in shares of Exactech by 11.1% during the second quarter. TIAA CREF Investment Management LLC now owns 34,438 shares of the medical equipment provider’s stock valued at $1,026,000 after acquiring an additional 3,444 shares in the last quarter. OxFORD Asset Management LLP raised its holdings in shares of Exactech by 17.8% during the second quarter. OxFORD Asset Management LLP now owns 59,972 shares of the medical equipment provider’s stock valued at $1,787,000 after acquiring an additional 9,082 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Exactech by 5.3% during the second quarter. Northern Trust Corp now owns 149,395 shares of the medical equipment provider’s stock valued at $4,452,000 after acquiring an additional 7,584 shares in the last quarter. Prudential Financial Inc. bought a new position in shares of Exactech during the second quarter valued at approximately $359,000. Finally, Schwab Charles Investment Management Inc. raised its holdings in shares of Exactech by 30.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 70,248 shares of the medical equipment provider’s stock valued at $2,094,000 after acquiring an additional 16,330 shares in the last quarter. Hedge funds and other institutional investors own 66.25% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/20/exactech-exac-cut-to-sell-at-bidaskclub.html.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.